NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

手掌多汗症的美國市場:洞察,流行病學,及至2030年的預測

Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030 (US)

出版商 DelveInsight Business Research LLP 商品編碼 971977
出版日期 按訂單生產 內容資訊 英文 65 Pages
商品交期: 10個工作天內
價格
手掌多汗症的美國市場:洞察,流行病學,及至2030年的預測 Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030 (US)
出版日期: 按訂單生產內容資訊: 英文 65 Pages
簡介

美國的手掌多汗症的市場規模,在2017年∼2030年的調查期間預計以大幅度的年複合成長率擴大。全球市場中美國佔大幅度,2017年達2億4,610萬美金。

美國確診的手掌多汗症的病例數,2017年為140萬7,107案例。其中77萬3,909案例為重症,63萬3,198案例非重症。

本報告提供美國的手掌多汗症市場的相關調查,疾病概要及流行病學,市場規模和預測,趨勢,成長要素及課題,機會,新的治療方法及開發活動,未滿足需求等資訊。

目錄

第1章 重要的洞察

第2章 摘要整理

第3章 SWOT分析

第4章 疾病的背景和概要

  • 簡介
  • 症狀
  • 病理學
  • 遺傳性傳達的證據
  • 生活品質
  • 診斷

第5章 流行病學和患者人口

  • 主要調查結果
  • 前提條件與理論性根據-美國
  • 美國
    • 美國的多汗症的盛行率
    • 美國的確診的手掌多汗症盛行率
    • 美國的手掌多汗症的各年齡病例
    • 美國的手掌多汗症的重症、特殊病例

第6章 治療

第7章 指南

第8章 未滿足需求

第9章 對手掌多汗症有貢獻的組織

第10章 病例報告

  • 多汗症:患者的病例
  • 多汗症

第11章 病患歷程

第12章 新治療方法

  • 主要的競爭
  • Dexmecamylamine: Atacama Therapeutics
    • 產品概要
    • 其他開發活動
    • 臨床開發
  • Qbrexza: Dermira, Inc.
    • 其他開發活動

第13章 市場分析

  • 主要調查結果
  • 市場預測:美國
    • 美國的市場規模

第14章 市場成長要素

第15章 市場障礙

第16章 償付

第17章 附錄

  • 參考文件
  • 報告的調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI1177

DelveInsight's 'Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Palmar Hyperhidrosis in the United States.

The Palmar Hyperhidrosis market report provides analysis regarding current treatment practices, an emerging drug, like Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), potential therapies, market share of the individual therapies, historical, current and forecasted Palmar Hyperhidrosis market size from 2017 to 2030 for the United States.

The report also covers current Palmar Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

  • The United States

Study Period: 2017-2030

Palmar Hyperhidrosis - Disease Understanding and Treatment Algorithm

Palmar Hyperhidrosis Overview

Palmar hyperhidrosis (PH) is a relatively common condition characterized by excessive hand sweating beyond normal thermoregulatory needs. Etiologically, the disorder can be primary (idiopathic) or secondary due to an underlying cause. Primary PH tends to arise in childhood or adolescence and usually persists throughout life. Despite its unknown origin, it is attributed to localized sympathetic hyperactivity on otherwise normal eccrine sweat glands, mainly triggered by emotional or thermal stimuli. Secondary PH occurs as a result of underlying pathology or medication use.

Inconvenience is experienced by patients with PH when there is a direct interference with activities involving the hands. Direct interference of sweating impacts work or school life due to difficulties with using computer keyboards, holding objects, working with paper documents, or giving handshakes.

Palmar Hyperhidrosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Palmar Hyperhidrosis market to treat the condition. It also provides the country-wise Palmar Hyperhidrosis treatment guidelines for the United States.

DelveInsight's Palmar Hyperhidrosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Palmar Hyperhidrosis treatment algorithms and treatment guidelines in the US.

Palmar Hyperhidrosis Epidemiology

The Palmar Hyperhidrosis epidemiology chapters provide insights about historical and current Palmar Hyperhidrosis patient pool and forecasted trends for US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Palmar Hyperhidrosis Palmar Hyperhidrosis epidemiology is segmented by Diagnosed Prevalent Cases of Palmar Hyperhidrosis, Diagnosed cases of Palmar Hyperhidrosis, cases of Palmar Hyperhidrosis by Age, and Severe cases of Palmar Hyperhidrosis. The report includes a thorough analysis of all segmentations.

In the US, the cases of Hyperhidrosis were 15,634,521 in 2017. Moreover, the total diagnosed prevalent cases of Palmar Hyperhidrosis in the United States were found to be 1,407,107 in 2017.

According to DelveInsight's analysis, In the United States, the highest number of Palmar Hyperhidrosis was reported to be among individuals above 18 years of age.

In the United States, out of all the total prevalent cases reported 773,909 severe and 633,198 non-severe cases for Palmar Hyperhidrosis in 2017.

Palmar Hyperhidrosis Drug Chapters

The drug chapter segment of the Palmar Hyperhidrosis report encloses the detailed analysis of the Palmar Hyperhidrosis pipeline drug. It also helps understand the Palmar Hyperhidrosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Palmar Hyperhidrosis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), etc. for the treatment of Palmar Hyperhidrosis in the pipeline.

Palmar Hyperhidrosis Market Outlook

The Palmar Hyperhidrosis market size is expected to increase at a significant CAGR during the study period (2017-2030). The United States accounts for the Palmar Hyperhidrosis market size, with USD 246.1 million in 2017.

Palmar Hyperhidrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Palmar Hyperhidrosis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Palmar Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the Palmar Hyperhidrosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Palmar Hyperhidrosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Palmar Hyperhidrosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Palmar Hyperhidrosis collaborations, acquisition and merger, licensing, patent details, and other information for Palmar Hyperhidrosis emerging therapies.

Reimbursement Scenario in Palmar Hyperhidrosis

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Palmar HyperhIdrosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Palmar Hyperhidrosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, the Palmar Hyperhidrosis market scenario is expected to alter across the USA due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Palmar Hyperhidrosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Palmar Hyperhidrosis Pipeline Analysis
  • Palmar Hyperhidrosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Palmar Hyperhidrosis Report Key Strengths

  • 11 years Forecast
  • The United States
  • Palmar Hyperhidrosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Palmar Hyperhidrosis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Palmar Hyperhidrosis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Palmar Hyperhidrosis total market size as well as market size by therapies across the United States during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across the United States, and which country will have the largest Palmar Hyperhidrosis market size during the forecast period (2017-2030)?
  • At what CAGR, the Palmar Hyperhidrosis market is expected to grow in the United States during the forecast period (2017-2030)?
  • What would be the Palmar Hyperhidrosis market outlook across the United States during the forecast period (2017-2030)?
  • What would be the Palmar Hyperhidrosis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Palmar Hyperhidrosis?
  • What is the historical Palmar Hyperhidrosis patient pool in the United States?
  • What would be the forecasted patient pool of Palmar Hyperhidrosis in the United States?
  • What will be the United States' growth opportunities with respect to the patient population pertaining to Palmar Hyperhidrosis?
  • At what CAGR is the population expected to grow in the US during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Palmar Hyperhidrosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Palmar Hyperhidrosis in the USA?
  • What is the Palmar Hyperhidrosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Palmar Hyperhidrosis?
  • How many therapies are developed by each company for Palmar Hyperhidrosis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Palmar hyperhidrosis treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Palmar hyperhidrosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Palmar hyperhidrosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Palmar hyperhidrosis?
  • What are the global historical and forecasted market of Palmar hyperhidrosis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Palmar hyperhidrosis market
  • To understand the future market competition in the Palmar hyperhidrosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Palmar hyperhidrosis in the United States.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • To understand the future market competition in the Palmar hyperhidrosis market

What is the forecasted Palmar hyperhidrosis market size in 2030?

DelveInsight estimates an increase in Palmar hyperhidrosis Market Size during the study period, 2017-2030

What are the present Palmar hyperhidrosis market drivers?

Topical Medication, Affecting the larger population and Ease of treatment

What are the Palmar hyperhidrosis market barriers?

Social and Professional Life, Lack of Etiology and Lack of Oral Medication

How many companies are developing drugs for Palmar hyperhidrosis?

Currently, there are many key pharma players engaged in developing the drug for Palmar hyperhidrosis in monotherapy.

Which are the leading companies in the Palmar hyperhidrosis market?

Key Players - Atacama Therapeutics, Dermira Inc

How is epidemiology segmented for Palmar hyperhidrosis?

Prevalent Cases of Palmar hyperhidrosis, Diagnosed cases of Palmar hyperhidrosis, Palmar hyperhidrosis cases by Age and Severity-specific cases Palmar hyperhidrosis.

Table of Contents

1. Key Insights

2. Executive Summary of Palmar Hyperhidrosis

3. SWOT Analysis for Palmar Hyperhidrosis

4. Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Symptoms
  • 4.3. Pathophysiology
  • 4.4. Evidence of genetic transmission
  • 4.5. Quality of life
  • 4.6. Diagnosis

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Assumptions and Rationale - United States
  • 5.3. The United States
    • 5.3.1. Prevalent Cases of Hyperhidrosis in the United States
    • 5.3.2. Diagnosed Prevalent Cases of Palmar Hyperhidrosis in the United States
    • 5.3.3. Age-specific Cases of Palmar Hyperhidrosis in the United States
    • 5.3.4. Severity-specific Cases of Palmar Hyperhidrosis in the United States

6. Treatment

7. Guidelines

8. Unmet Needs

9. Organizations contributing toward Palmar Hyperhidrosis

10. Case Reports

  • 10.1. Hyperhidrosis: A Patient Case
  • 10.2. Hyperhidrosis

11. Patient Journey

  • 11.1. Patient Journey: General

12. Emerging Therapies

  • 12.1. Key Competitors
  • 12.2. Dexmecamylamine: Atacama Therapeutics
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
  • 12.3. Qbrexza: Dermira, Inc.
    • 12.3.1. Product Description
    • 12.3.2. Other Development Activities
    • 12.3.3. Clinical Development

13. Palmar Hyperhidrosis: Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Outlook: The United States
    • 13.2.1. The United States Market Size

14. Market Drivers

15. Market Barriers

16. Reimbursement

17. Appendix

  • 17.1. Bibliography
  • 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1: Summary of Palmar Hyperhidrosis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Patient characteristics
  • Table 3: Ethnicity of patients with Hyperhidrosis
  • Table 4: Prevalent Cases of Hyperhidrosis in the United States (2017-2030)
  • Table 5: Diagnosed Prevalent Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Table 6: Age-specific Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Table 7: Severity-specific Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Table 8: Summary of Available Treatment Options for Palmar Hyperhidrosis
  • Table 9: Organizations contributing to Palmar Hyperhidrosis in the United States
  • Table 10: AT-5214, Clinical Trial Description, 2020
  • Table 11: Qbrexza, Clinical Trial Description, 2020
  • Table 12: United States Market Size of Palmar Hyperhidrosis in USD Million (2017-2030)
  • Table 13: The US Market Size of Palmar Hyperhidrosis by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Scheme of the histological aspect of eccrine and apocrine sweat glands, and their relation to the skin structure
  • Figure 3: Scheme of the sympathetic pathway of sweat control.
  • Figure 4: Pedigrees illustrating a particularly strong degree of familial aggregation
  • Figure 5: Prevalent Cases of Hyperhidrosis in the United States (2017-2030)
  • Figure 6: Diagnosed Prevalent Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Figure 7: Age-specific Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Figure 8: Severity-specific Cases of Palmar Hyperhidrosis in the United States (2017-2030)
  • Figure 9: Treatment Algorithm
  • Figure 10: Treatment Algorithm for Palmar Hyperhidrosis
  • Figure 11: Unmet Needs of Palmar Hyperhidrosis
  • Figure 12: Market Size of Palmar Hyperhidrosis in the United States, USD Million (2017-2030)
  • Figure 13: The US Market Size of Palmar Hyperhidrosis by Therapies in USD Million (2017-2030)
  • Figure 14: Market Drivers of Palmar Hyperhidrosis
  • Figure 15: Market Drivers of Palmar Hyperhidrosis